A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

ClinicoEconomics and Outcomes Research

Volumn 1, Issue 1, 2009, Pages 53-59

  Colombo, Giorgio L ^a   Di Matteo, Sergio ^b   Peris, Ketty ^c   Fargnoli, Maria Concetta ^c   Esposito, Maria ^d   Mazzotta, Annamaria ^d   Chimenti, Sergio ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAVE Studi Analisi Valutazioni Economiche   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cost effectiveness; Cost utility; Etanercept; Markov model; Psoriasis

Indexed keywords

ETANERCEPT;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE; HOSPITALIZATION; HUMAN; ITALY; PSORIASIS; PSORIASIS VULGARIS; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 77953460695     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s7348     Document Type: Review

References (20)

1. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-1204.
2. Smith CH, Barker JN. Psoriasis and its management. BMJ. 2006;333(7564):380-384.
3. Smith CH, Anstey AV, Barker JN, et al. For British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005; 153(3):486-497.
4. Thaçi D. Long-term data in the treatment of psoriasis. Br J Dermatol. 2008;159(Suppl 2):18-24.
5. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5-21.
6. European Medicines Agency. Annex 1: Summary of product characteristics (Enbrel). Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Enbrel/ emea-combined-h262en.pdf. Accessed on September 10, 2009.
7. European Medicines Agency. Annex 1: Summary of product characteristics (Remicade). Available from: http://www.emea.europa. eu/humandocs/PDFs/EPAR/ Remicade/emea-combined-h240en.pdf. Accessed on September 10, 2009.
8. European Medicines Agency. Annex 1: Summary of product characteristics (Humira). Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/humira/ emea-combined-h481en.pdf. Accessed on September 10, 2009.
9. Papp KA, Tyring S, Lahfa M, et al; for Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304-1312.
10. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1-233, i-iv.
11. Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol. 2009;160(2):380-386.
12. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627-1632.
13. Leonardi CL, Powers JL, Matheson RT, et al; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. New Eng J Med. 2003;349 (21):2014-2022.
14. Colombo GL, Altomare GF. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4(2): 559-568.
15. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York, NY: Oxford; 1987: p. 165.
16. Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol. 1995;131(5):561-568.
17. Colombo GL, Muzio A, Longhi A. Valutazione economica di Infliximab (Remicade® ) vs Etanercept (Enbrel® ) nel trattamento dell'artrite reumatoide. Farmeconomia e percorsi terapeutici. 2003;4(2): 189-198.
18. National Institute of Statistics. Italian inflation rates. Available from: http://www.istat.it/prezzi/precon/rivalutazioni. 2008. Accessed February 12, 2009.
19. Lucioni C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico? PharmacoEconomics - Italian Research Articles. 2004;(3):121-130.
20. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: Stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmaco Economics - Italian Research Articles. 2003;5:53-67.